MedTrace Logo

Safety, Pharmacokinetic Study of PRIC in Healthy Adult Subjects

NCT03826485 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2019-02-01

No results posted yet for this study

Summary

The purpose of this study is Safety, Pharmacokinetic Study of PRIC

Conditions

  • Healthy

Interventions

DRUG

PRIC

Pranlukast hydrate 50mg

DRUG

Pranlukast hydrate

Pranlukast hydrate 225mg/2.25g

Sponsors & Collaborators

  • SamA Pharmaceutical Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2019-04-25
Completion
2019-07-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03826485 on ClinicalTrials.gov